Latest Conference Articles

The use of a ctDNA assay could help determine which patients with colorectal cancer may benefit most from chemotherapy after surgery.

Gut Microbiome Makeup May Help Predict Skin-Related Immunotherapy Side Effects in Patients With Gastric Cancer

January 24th 2022, 4:00pm

Patients with gastric cancer who present with certain bacteria in their gut were found to be more likely to experience skin-related side effects from Opdivo treatment, research showed.

Patients With Unresectable Liver Cancer May Have a ‘Promising and Tolerable’ Treatment Option With Combination Therapy

January 24th 2022, 2:21pm

The use of a non-invasive procedure combined with Lenvima plus Tyvyt demonstrated safe and effective results in patients with liver cancer not eligible for surgical resection.

Lenvima May Offer Survival Benefit With Manageable Side Effects in Recurrent HCC After Liver Transplantation

January 23rd 2022, 3:00pm

Researchers observed this benefit in recurrent HCC after liver transplantation, which represents a patient population often excluded from clinical trials due to potential organ rejection.

Frontline Lenvima Provided Survival Benefit for Patients With Liver Cancer

January 22nd 2022, 3:00pm

Treating patients with liver cancer initially with Lenvima instead of the standard of care was associated with a survival benefit, according to recent research.

Minimally Invasive Procedure Combined with Lenvima and Checkpoint Blockade Shows Promise in Unresectable Liver Cancer

January 21st 2022, 10:00pm

The use of a minimally invasive procedure — known as trans-arterial chemoembolization — plus Lenvima and a PD-1 checkpoint blockade drug proved to be safe and efficacious in patients with unresectable advanced liver cancer.

Enhertu Linked to Sustained Survival Benefit in Gastroesophageal, Gastric Cancer Subset

January 21st 2022, 2:00pm

The use of Enhertu was associated with a reduction in the risk of death compared with standard chemotherapy in certain patients with gastroesophageal and gastric cancer.

Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’

January 6th 2022, 2:00pm

An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.

Aromatase Inhibitors Reduce Recurrence Risk, But Not Death Rates, in Premenopausal Patients With Breast Cancer

January 5th 2022, 8:15pm

Premenopausal women with ER-positive breast cancer experienced a decreased rate of recurrence when given an aromatase inhibitor, compared with those given tamoxifen. However, more research is still needed, an expert said.

Upfront Darzalex Combo May Be More Beneficial in the First-Line Setting for Transplant-Ineligible Myeloma Than Alternatives

January 5th 2022, 5:00pm

An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.

Novel Drug Combo Induces Encouraging Results in Patients With Heavily Pretreated Breast Cancer

January 3rd 2022, 10:00pm

The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.

Second-Line Enhertu May Be ‘Standard of Care’ for Patients with HER2-Positive Metastatic Breast Cancer

December 28th 2021, 4:00pm

The use of Enhertu may also be beneficial across HER2-positive metastatic breast cancer subgroups including patients with and without brain metastases.

Study Results Champion Keytruda/Chemo as ‘New Standard of Care’ in TNBC Subset

December 27th 2021, 10:00pm

The combination of Keytruda and chemotherapy improved survival rates in patients with PD-L1—positive metastatic triple-negative breast cancer.

Pre-Surgical Keytruda Provides Promising Advancement in TNBC Treatment

December 20th 2021, 8:00pm

Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.

CAR-T Cell Therapy Continues to Impress in Myeloma Treatment

December 15th 2021, 7:00pm

Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.

$Venclexta-Triplet Combo Appears Safe And Shows Deep Responses in Type of Relapsed/Refractory Multiple Myeloma$

Venclexta-Triplet Combo Appears Safe And Shows Deep Responses in Type of Relapsed/Refractory Multiple Myeloma

December 15th 2021, 2:00pm

Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma.

New Treatment Regimen May Reduce GvHD, the ‘Most Common and Feared Complication’ of Stem Cell Transplantation

December 14th 2021, 10:00pm

The addition of a drug commonly used to treat arthritis may reduce the risk of graft-versus-host-disease in patients who underwent haploidentical allogeneic stem cell transplant.

$Calquence Remains Effective and Safe After 3 Years Compared With Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia$

Calquence Remains Effective and Safe After 3 Years Compared With Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia

December 14th 2021, 8:00pm

Calquence, a next-generation BTK inhibitor, significantly prolonged survival compared with standard of care, along with no new side effects at three years in chronic lymphocytic leukemia. These findings also pertained to some patients with high-risk genetic features.

Imbruvica And Rituxan Bests Standard-of-Care Regimen in Patients With Previously Untreated CLL

December 14th 2021, 2:00pm

The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.

$Novel Drug Plus Rituxan May Serve as ‘New Treatment Option’ for Relapsed/Refractory Lymphoma Subset$

Novel Drug Plus Rituxan May Serve as ‘New Treatment Option’ for Relapsed/Refractory Lymphoma Subset

December 13th 2021, 10:00pm

The use of a novel drug combination yielded positive outcomes in patients with B-cell lymphomas for whom CAR-T cell therapy or stem cell transplant isn’t an option.

mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS

December 13th 2021, 9:00pm

Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.

Ninlaro-Darzalex Combo Elicits Favorable Treatment Outcomes, Responses in Newly Diagnosed Multiple Myeloma

December 13th 2021, 8:00pm

Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

Patients With CLL Had Improved Quality of Life on Imbruvica Plus Rituxan

December 13th 2021, 2:30pm

Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.

Novel Treatment Combination Shows Promising Results, Tolerable Side Effects in Multiple Myeloma

December 12th 2021, 10:00pm

Patients with relapsed or refractory multiple myeloma experienced a benefit after receiving Xpovio in combination with Darzalex, Velcade and the steroid dexamethasone.

Some Treatment Outcomes Do Not Differ Between Black and White Patients With Breast Cancer, But Disparities Persist

December 12th 2021, 8:00pm

Study results showed that pathologic complete response rates were not significantly different between Black and White patients with high-risk breast cancer, but disparities still exist for other treatment outcomes.

Kymriah May Be Safe and Effective in Children and Young Adults With Acute Lymphoblastic Leukemia Subtype

December 12th 2021, 5:11pm

The immunotherapy Kymriah offered similar benefits in patients younger than and older than 18 years with relapsed/refractory B-cell acute lymphoblastic leukemia.

Cancer Clinical Trial Enrollment Is Low in the US, and Patient Depression and Anxiety May Play a Role

December 12th 2021, 3:00pm

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

$MRD-Guided Combination Treatment Appears Feasible in Patients With a Form of Relapsed/Refractory Leukemia$

MRD-Guided Combination Treatment Appears Feasible in Patients With a Form of Relapsed/Refractory Leukemia

December 11th 2021, 10:00pm

Using the presence of minimal residual disease to direct Imbruvica plus Venclexta treatment appears to be a feasible option for patients with relapsed/refractory chronic lymphocytic leukemia.

Imbruvica, Venclexta Combo Offers Chemotherapy-Free Regimen for Patients with CLL

December 11th 2021, 6:34pm